Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Bioorg Med Chem ; 4(6): 851-8, 1996 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-8818234

RESUMO

A series of 2,5-diarylisothiazolones is reported that inhibit the IL-1 beta-induced breakdown of bovine nasal septum cartilage in an organ culture assay. The synthesis and preliminary SAR of these compounds are described. These compounds represent a novel, nonpeptide lead series approach to the mediation of the chronic cartilage breakdown associated with arthritic disease. These compounds are relatively resistant to reductive metabolism by liver microsomal preparations and appear to inhibit cartilage breakdown by interfering with the proteolytic activation of matrix metalloproteinases.


Assuntos
Cartilagem/efeitos dos fármacos , Inibidores Enzimáticos/farmacologia , Interleucina-1/metabolismo , Tiazóis/farmacologia , Animais , Cartilagem/metabolismo , Bovinos , Hidrólise , Interleucina-1/antagonistas & inibidores , Espectroscopia de Ressonância Magnética , Técnicas de Cultura de Órgãos , Osteoartrite/metabolismo , Osteoartrite/prevenção & controle , Espectrofotometria Infravermelho , Relação Estrutura-Atividade , Tiazóis/química
2.
Bioorg Med Chem ; 3(3): 227-34, 1995 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-7606384

RESUMO

A series of 2-(arylmethyl)pyridoisothiazolones is reported that inhibit the IL-1 beta induced breakdown of bovine nasal septum cartilage in an organ culture assay. The synthesis and preliminary SAR of these compounds are described. These compounds represent a novel, non-peptide lead series approach to the mediation of the chronic cartilage breakdown associated with arthritic disease. These compounds are relatively resistant to reductive metabolism by liver microsomal preparations and appear to inhibit cartilage breakdown by interfering with the proteolytic activation of matrix metalloproteinases.


Assuntos
Cartilagem/metabolismo , Piridinas/farmacologia , Tiazóis/farmacologia , Animais , Bovinos , Indometacina/farmacologia , Interleucina-1/antagonistas & inibidores , Interleucina-1/metabolismo , Metaloproteinase 3 da Matriz , Metaloendopeptidases/antagonistas & inibidores , Metaloendopeptidases/metabolismo , Microssomos/metabolismo , Naproxeno/farmacologia , Septo Nasal , Técnicas de Cultura de Órgãos , Oxirredução/efeitos dos fármacos , Proteoglicanas/metabolismo , Pirazóis/farmacologia , Piridinas/síntese química , Piridinas/química , Relação Estrutura-Atividade , Tiazóis/síntese química , Tiazóis/química
3.
J Med Chem ; 37(19): 3071-8, 1994 Sep 16.
Artigo em Inglês | MEDLINE | ID: mdl-7932530

RESUMO

The synthesis, biological evaluation, and structure-activity relationships of a series of N-phenyl heteroaryl-fused isothiazolones are described. These isothiazolones have been shown to exhibit potent, dose-dependent inhibition of IL-1 beta-induced breakdown of proteoglycan in a cartilage organ culture assay. This effect is likely due to inhibition of MMP activation and a consequent reduction in MMP activity following IL-1 beta stimulation. Thus these compounds potentially represent simple, non-peptidic disease-modifying agents for the treatment of arthritic diseases. To examine the effects of structure on in vitro activity, three general features of the molecules were varied, substituents on the pendant N-phenyl group, the position of ring fusion to the isothiazolone, and substituents on the fused ring peri to the isothiazolone sulfur.


Assuntos
Cartilagem/efeitos dos fármacos , Cartilagem/metabolismo , Tiazóis/síntese química , Tiazóis/farmacologia , Animais , Bovinos , Relação Dose-Resposta a Droga , Humanos , Interleucina-1/antagonistas & inibidores , Interleucina-1/toxicidade , Isomerismo , Masculino , Metaloendopeptidases/farmacologia , Modelos Biológicos , Proteoglicanas/metabolismo , Piridinas/síntese química , Piridinas/farmacologia , Pirimidinas/síntese química , Pirimidinas/farmacologia , Ratos , Relação Estrutura-Atividade
4.
Agents Actions ; 27(3-4): 344-6, 1989 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-2801321

RESUMO

The purpose of this study was to investigate the effects of cyclosporine A (CSA) and methotrexate (MTX) as potential immunomodulators in a nonestablished adjuvant arthritis (AA) model. Non-injected hind paw volumes were reduced when AA rats were treated for 18 days with CSA (100% at 10 mg/kg) or MTX (100% at 0.1 mg/kg). Body weights of drug treated AA rats were increased above untreated AA rats and were similar to non-arthritic controls. AA rats show elevated T helper (W3/25+)/T suppressor (OX 8+) cell ratios (2.0 vs. 3.1, p less than 0.01). The immunomodulators tested all returned these elevated ratios to control non-arthritic levels. Similarly, these drugs returned the reduced mitogen responses and elevated blood granulocyte numbers toward normal non-arthritic control values.


Assuntos
Artrite Experimental/tratamento farmacológico , Imunossupressores/uso terapêutico , Animais , Artrite , Artrite Experimental/patologia , Artrite Experimental/fisiopatologia , Ciclosporinas/uso terapêutico , Pé/patologia , Indometacina/uso terapêutico , Masculino , Metotrexato/uso terapêutico , Ratos , Ratos Endogâmicos , Linfócitos T/efeitos dos fármacos , Linfócitos T/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...